Płuzańska A, Stempczyńska J, Szmigielski S, Luczak M, Jeljaszewicz J, Pulverer G
Anticancer Res. 1985 Sep-Oct;5(5):521-6.
50 patients with advanced metastatic breast cancer were matched into 25 "twin" pairs. In each pair, one "twin" received chemotherapy (FAC) and the other received chemoimmunotherapy (FAC + intratumorally Propionibacterium granulosum KP-45 (PG)). The therapeutic effects of this 2-year follow-up study were carefully documented and analysed. The mean survival time of FAC + PG-treated patients was about 17 months as compared to 8.5 months in FAC controls. PG-therapy responders showed increasing values of T-lymphocytes in peripheral blood, as well as higher blast transformation indices than nonresponders and controls. The skin reactivity to PHA, Distreptase, and Tuberculin was markedly enhanced in the FAC + PG-group. The incidence rate of hematological and/or infectious complications was significantly lower in PG-treated patients than in the controls. Local PG-immunotherapy was proven beneficial in advanced breast cancer when combined with FAC-chemotherapy, providing better toleration of chemotherapy and lower risk of myelosuppression and infections.
50例晚期转移性乳腺癌患者被配对成25对“双胞胎”。每对中，一个“双胞胎”接受化疗（FAC），另一个接受化学免疫疗法（FAC + 瘤内注射颗粒丙酸杆菌KP - 45（PG））。对这项为期2年的随访研究的治疗效果进行了仔细记录和分析。接受FAC + PG治疗的患者的平均生存时间约为17个月，而FAC对照组为8.5个月。PG治疗有反应者外周血中T淋巴细胞值增加，且其母细胞转化指数高于无反应者和对照组。FAC + PG组对PHA、链激酶和结核菌素的皮肤反应性明显增强。接受PG治疗的患者血液学和/或感染并发症的发生率明显低于对照组。局部PG免疫疗法与FAC化疗联合应用时，被证明对晚期乳腺癌有益，可提高化疗耐受性，降低骨髓抑制和感染风险。
